AR097840A1 - Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit - Google Patents
Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kitInfo
- Publication number
- AR097840A1 AR097840A1 ARP140103607A ARP140103607A AR097840A1 AR 097840 A1 AR097840 A1 AR 097840A1 AR P140103607 A ARP140103607 A AR P140103607A AR P140103607 A ARP140103607 A AR P140103607A AR 097840 A1 AR097840 A1 AR 097840A1
- Authority
- AR
- Argentina
- Prior art keywords
- growth hormone
- human growth
- formulation
- long
- conjugate
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 16
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 16
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 16
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 title abstract 8
- 230000000694 effects Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 4
- 102000018358 immunoglobulin Human genes 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una formulación de un conjugado de hormona de crecimiento humana de acción prolongada (hGH), que comprende un conjugado de hormona de crecimiento humana de acción prolongada (hGH), en que la hormona de crecimiento humana fisiológicamente activa (hGH) se une a una región Fc de inmunoglobulina, un tampón, un tensioactivo no iónico y un alcohol de azúcar. Reivindicación 2: La formulación de un conjugado de hormona de crecimiento humana de acción prolongada de acuerdo con la reivindicación 1, en la que la formulación es una formulación liofilizada de un conjugado de hormona de crecimiento humana de acción prolongada, que comprende una mezcla liofilizada de una solución acuosa que comprende un conjugado de hormona de crecimiento humana de acción prolongada (hGH) en que la hGH fisiológicamente activa se une a una región Fc de inmunoglobulina y una solución libre de albúmina que comprende un tampón, un tensioactivo no iónico y un alcohol de azúcar. Reivindicación 12: La formulación de un conjugado de hormona de crecimiento humana de acción prolongada de acuerdo con la reivindicación 2, en la que la solución libre de albúmina también comprende al menos uno seleccionado del grupo que consiste en un azúcar, un alcohol polihídrico y un aminoácido. Reivindicación 13: La formulación de un conjugado de hormona de crecimiento humana de acción prolongada de acuerdo con la reivindicación 12, en la que el aminoácido es histidina o glicina. Reivindicación 32: La formulación de un conjugado de hormona de crecimiento humana de acción prolongada de acuerdo con la reivindicación 1, 2 ó 20, en la que la región Fc de inmunoglobulina es una región Fc derivada de IgG, IgA, lgD, lgE o lgM. Reivindicación 36: La formulación de un conjugado de hormona de crecimiento humana de acción prolongada de acuerdo con la reivindicación 32, en la que la región Fc de inmunoglobulina es una región Fc de IgG4 humana aglicosilada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130115177 | 2013-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR097840A1 true AR097840A1 (es) | 2016-04-20 |
Family
ID=52743982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140103607A AR097840A1 (es) | 2013-09-27 | 2014-09-29 | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit |
Country Status (15)
Country | Link |
---|---|
US (2) | US10987425B2 (es) |
EP (2) | EP3050559B1 (es) |
JP (1) | JP6549104B2 (es) |
KR (1) | KR102276304B1 (es) |
CN (2) | CN114288254A (es) |
AR (1) | AR097840A1 (es) |
AU (1) | AU2014329003A1 (es) |
BR (1) | BR112016006455A2 (es) |
CA (1) | CA2925416A1 (es) |
HK (1) | HK1225976A1 (es) |
IL (1) | IL244769A0 (es) |
MX (1) | MX2016003705A (es) |
RU (1) | RU2683823C2 (es) |
TW (1) | TW201605468A (es) |
WO (1) | WO2015046974A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
SG11201608120TA (en) * | 2014-03-31 | 2016-11-29 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技(上海)有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
KR20210144606A (ko) * | 2020-05-22 | 2021-11-30 | 한미약품 주식회사 | 글루카곤 유도체의 지속형 결합체의 액상 제제 |
CN115845032A (zh) * | 2022-10-28 | 2023-03-28 | 深圳科兴药业有限公司 | 生长激素fc融合蛋白注射液及其用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
JPH10265404A (ja) * | 1996-02-02 | 1998-10-06 | Mitsui Chem Inc | ヒト成長ホルモンを含有する医薬製剤 |
AUPN801296A0 (en) * | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US20070179096A1 (en) | 1996-04-24 | 2007-08-02 | Novo Nordisk A/S | Pharmaceutical Formulation |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
SE9704405D0 (sv) * | 1997-11-28 | 1997-11-28 | Pharmacia & Upjohn Ab | New syringe |
RU2190129C2 (ru) | 2000-10-17 | 2002-09-27 | Открытое акционерное общество "Павловский машиностроительный завод "Восход" | Резервированный электрогидравлический привод |
CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
ES2438098T3 (es) | 2003-11-13 | 2014-01-15 | Hanmi Science Co., Ltd. | Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo |
WO2005063298A1 (en) * | 2003-12-23 | 2005-07-14 | Pharmacia Corporation | Stable growth hormone liquid formulation |
CA2594561C (en) | 2004-12-22 | 2014-12-23 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
JP4283776B2 (ja) * | 2005-03-07 | 2009-06-24 | ラボラトワール セローノ ソシエテ アノニム | Hgh含有医薬組成物 |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
CA2618068C (en) * | 2005-08-05 | 2016-02-16 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
EP2032606B1 (en) * | 2006-05-30 | 2013-11-27 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
BR112012014721B1 (pt) * | 2009-12-15 | 2022-06-28 | Ascendis Pharma Endocrinology Division A/S | Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
EP2606908A1 (en) * | 2011-12-19 | 2013-06-26 | Ipsen Pharma S.A.S. | Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH) |
US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
-
2014
- 2014-09-26 BR BR112016006455A patent/BR112016006455A2/pt not_active Application Discontinuation
- 2014-09-26 WO PCT/KR2014/009059 patent/WO2015046974A1/ko active Application Filing
- 2014-09-26 KR KR1020140129476A patent/KR102276304B1/ko active IP Right Grant
- 2014-09-26 MX MX2016003705A patent/MX2016003705A/es unknown
- 2014-09-26 US US15/025,127 patent/US10987425B2/en active Active
- 2014-09-26 JP JP2016518140A patent/JP6549104B2/ja active Active
- 2014-09-26 CN CN202210040339.9A patent/CN114288254A/zh active Pending
- 2014-09-26 TW TW103133464A patent/TW201605468A/zh unknown
- 2014-09-26 RU RU2016113684A patent/RU2683823C2/ru not_active IP Right Cessation
- 2014-09-26 CA CA2925416A patent/CA2925416A1/en not_active Abandoned
- 2014-09-26 EP EP14847086.7A patent/EP3050559B1/en active Active
- 2014-09-26 AU AU2014329003A patent/AU2014329003A1/en not_active Abandoned
- 2014-09-26 CN CN201480064028.XA patent/CN105848645A/zh active Pending
- 2014-09-26 EP EP20166812.6A patent/EP3689335A1/en active Pending
- 2014-09-29 AR ARP140103607A patent/AR097840A1/es unknown
-
2016
- 2016-03-27 IL IL244769A patent/IL244769A0/en unknown
- 2016-12-16 HK HK16114361A patent/HK1225976A1/zh unknown
-
2020
- 2020-12-28 US US17/135,468 patent/US20210138070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3050559A4 (en) | 2017-05-31 |
CN105848645A (zh) | 2016-08-10 |
RU2016113684A (ru) | 2017-11-01 |
IL244769A0 (en) | 2016-04-21 |
JP6549104B2 (ja) | 2019-07-24 |
EP3050559A1 (en) | 2016-08-03 |
MX2016003705A (es) | 2016-05-16 |
BR112016006455A2 (pt) | 2017-08-01 |
RU2683823C2 (ru) | 2019-04-02 |
US20210138070A1 (en) | 2021-05-13 |
US20160213789A1 (en) | 2016-07-28 |
JP2016533345A (ja) | 2016-10-27 |
TW201605468A (zh) | 2016-02-16 |
HK1225976A1 (zh) | 2017-09-22 |
EP3050559B1 (en) | 2020-06-03 |
CN114288254A (zh) | 2022-04-08 |
KR102276304B1 (ko) | 2021-07-14 |
CA2925416A1 (en) | 2015-04-02 |
AU2014329003A1 (en) | 2016-05-12 |
EP3689335A1 (en) | 2020-08-05 |
RU2016113684A3 (es) | 2018-06-28 |
US10987425B2 (en) | 2021-04-27 |
WO2015046974A1 (ko) | 2015-04-02 |
KR20150035681A (ko) | 2015-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
AU2017279583B2 (en) | Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment | |
ECSP23041058A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
PE20060879A1 (es) | Formulacion anticuerpo anti a beta | |
PH12014502778B1 (en) | Antibody formulation | |
AR079746A1 (es) | Formulacion farmaceutica de anticuerpo | |
TN2009000382A1 (en) | Stable antibody formulations | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
PE20140734A1 (es) | Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas | |
AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
RU2017101667A (ru) | Фармацевтические композиции | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
TH138064A (th) | สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง | |
TH162100B (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |